A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

Inclusion Criteria: Inclusion Criteria for Participants Rolling Over from the Pivotal Efficacy Studies (TV48125-CNS-30082 or TV48125-CNS-30083): * Participants have completed the pivotal efficacy study and, in the opinion of the Investigator or the Sponsor, are able to complete the study in a safe and compliant way. * Participants may continue with a stable dose/regimen of the preventive medication they were taking during the pivotal efficacy studies. * The participant continues to meet appropriate criteria carried forward from the pivotal efficacy study/ * The participant has received all recommended age-appropriate vaccines according to local standard of care and schedule. * The participant weighs at least 17.0 kg on the day of study enrollment. NOTE: Additional criteria apply; please contact the investigator for more information. Inclusion Criteria for Participants Rolling Over from the Phase 1 Pediatric Pharmacokinetic Study (Study TV48125-CNS-10141): * The participant/caregiver has demonstrated compliance with the electronic headache diary during the 28-day baseline period by entry of headache data on a minimum of 21 out of 28 days (approximately 75% diary compliance). * The participant has received all recommended age-appropriate vaccines according to local standard of care and schedule. * The participant weighs at least 17.0 kg on the day of study enrollment. * The participant has a body mass index ranging from the 5th to 120% of the 95th percentile, inclusive, on…